MiST1: A phase IIa trial of rucaparib in patients harbouring BAP1/BRCA1 deficient relapsed malignant mesothelioma.

Authors

null

Dean Anthony Fennell

University Hospitals of Leicester, Leicester, United Kingdom

Dean Anthony Fennell , Liz Darlison , Peter Wells-Jordan , Catherine Jane Richards , Aarti Gaba , Charlotte Poile , Caroline Cowley , Alan G Dawson , Molly Scotland , Vina Bhundia , Bruno Morgan , Sarah Anthony , Adrian Nicholson , Cassandra Brookes , Seid Mohammed , Amy Branson , Amy King , Anne L. Thomas

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2020 ASCO Virtual Scientific Program

Session Type

Poster Session

Session Title

Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers

Track

Lung Cancer

Sub Track

Mesothelioma

Clinical Trial Registration Number

NCT03654833

Citation

J Clin Oncol 38: 2020 (suppl; abstr 9057)

DOI

10.1200/JCO.2020.38.15_suppl.9057

Abstract #

9057

Poster Bd #

250

Abstract Disclosures

Similar Posters

Poster

2021 ASCO Annual Meeting

A phase II trial of abemaciclib in patients with p16ink4a negative, relapsed mesothelioma.

A phase II trial of abemaciclib in patients with p16ink4a negative, relapsed mesothelioma.

First Author: Dean Anthony Fennell

First Author: Dean Anthony Fennell

First Author: Marjorie Glass Zauderer